2024
Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
Cosgun K, Robinson M, Agadzhanian N, Berning P, Fonseca-Arce D, Leveille E, Kothari S, Davids M, Jellusova J, Müschen M. Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies. Blood 2024, 144: 1412. DOI: 10.1182/blood-2024-208598.Peer-Reviewed Original ResearchProtein degradationRepression of MYCTranscriptional repression of MYCTranscriptional repressionPromote survivalProteasome inhibitorsProtein degradation pathwaysCell typesN-terminal residuesInduce cell deathRefractory B-cell malignanciesB-cateninB-cell malignanciesRNAi screenInteractome studiesB cell selectionRepressive complexesGene dependenciesProteasomal degradationB cellsChemogenomic screensProteasome inhibitor bortezomibActivated mycDeletion of Ctnnb1Cell death
2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2018, 18: 569-575.e1. PMID: 30122201, PMCID: PMC11673799, DOI: 10.1016/j.clml.2018.05.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesSalvage TherapySurvival RateVorinostatConceptsLarge B-cell lymphomaPhase II trialStable diseaseProgressive diseaseB-cell lymphomaPartial responseII trialCohort BCohort ADay 1Median progression-free survivalNonrandomized phase II trialDiffuse large B-cell lymphomaProgression-free survivalHistone deacetylase inhibitor vorinostatOverall response rateCombination of bortezomibMantle cell lymphomaNF-κB activationProteasome inhibitor bortezomibCell lymphoma cellsPresent multicenterRefractory MCLClinical responseCohort C
2016
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.Peer-Reviewed Original ResearchProgression-free survivalSelective estrogen receptor downregulatorsMetastatic breast cancerER-positive metastatic breast cancerMedian progression-free survivalArm ABreast cancerArm BHormone receptor-positive metastatic breast cancerRandomized phase II trialPhase II trialEstrogen receptor downregulatorsProteasome inhibitor bortezomibPFS ratesII trialConsortium TrialHazard ratioPostmenopausal womenPreclinical modelsInhibitor bortezomibBortezomibCancerProteasome inhibitorsAdditional evaluationTrials
2015
Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma
Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.Peer-Reviewed Original ResearchCardiac adverse eventsIndependent risk factorCardiac eventsCumulative incidenceRisk factorsMultiple myelomaPrior historyAdverse eventsAntithrombotic therapyPI therapyMedian durationPrior linesMore patientsMale genderAtherosclerotic cardiovascular disease riskC groupCardiac Toxicity AssociatedMedian prior linesLipid-lowering medicationsB groupCardiovascular disease riskStem cell transplantationCourse of treatmentProteasome inhibitor bortezomibIncidence of PI
2014
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure
Chaanine A, Nonnenmacher M, Kohlbrenner E, Jin D, Kovacic J, Akar F, Hajjar R, Weber T. Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. Gene Therapy 2014, 21: 379-386. PMID: 24572786, PMCID: PMC3976435, DOI: 10.1038/gt.2014.7.Peer-Reviewed Original ResearchConceptsHeart failureCardiac functionRodent heart failure modelsRat cardiomyocytesHeart failure modelPressure overload modelEffect of bortezomibProteasome inhibitor bortezomibNeonatal rat cardiomyocytesAdult rat cardiomyocytesWestern blot analysisSERCA2a proteinPressure-volume analysisSERCA2a levelsBortezomib treatmentConcurrent treatmentSERCA2a mRNAInhibitor bortezomibBortezomibHeart samplesHuman SERCA2aSerotype 1Proteasome inhibitorsAAV serotypes 1Proteasome inhibition
2013
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma
Poklepovic A, Youseffian L, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, Ernstoff MS, Roberts JD. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Investigational New Drugs 2013, 31: 937-942. PMID: 23315028, PMCID: PMC3844155, DOI: 10.1007/s10637-012-9913-8.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasPhase I trialTissue sarcomasPartial responseI trialPhase II dosesDurable complete responseAmine precursor uptakeTwenty-eight patientsProteasome inhibitor bortezomibHuman melanoma cell linesMurine xenograft tumor modelXenograft tumor modelCKIT mutationsDecarboxylation (APUD) tumorsProphylactic antiemeticsRECIST v1.0Eight patientsComplete responseMelanoma cell linesWeekly dosesDose escalationAgent dacarbazinePreclinical studiesDose levels
2011
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Holkova B, Perkins E, Sokol L, Richards K, Parekh S, Elstrom R, Badros A, Espinoza-Delgado I, Schell M, Kimball A, Tombes M, Shrader E, Sankala H, Coppola D, Kmieciak M, Sullivan D, Roberts J, Grant S. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood 2011, 118: 779. DOI: 10.1182/blood.v118.21.779.779.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaRefractory diffuse large B-cell lymphomaMantle cell lymphomaLarge B-cell lymphomaB-cell lymphomaResponse rateCohort BCohort ACell lymphomaDay 1Common treatment-related adverse eventsPan-HDAC inhibitor vorinostatTreatment-related adverse eventsCommon grade 3Peripheral sensory neuropathyPhase II studySpeakers bureauECOG performance scorePhase II trialSchedule of administrationPhase I studiesCombination of bortezomibNumerous preclinical studiesB-cell malignanciesProteasome inhibitor bortezomib
2009
Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm.
Germain D, Bahadur U, Halpern M, Adelson K, Raptis G, Waxman S, Ishii Y. Bortezomib Enhances the Efficacy of Fulvestrant by Promoting the Aggregation of the Estrogen Receptor in the Cytoplasm. Cancer Research 2009, 69: 5142-5142. DOI: 10.1158/0008-5472.sabcs-09-5142.Peer-Reviewed Original ResearchEfficacy of fulvestrantEstrogen receptorAromatase inhibitorsBreast cancer mouse modelPost-menopausal womenCancer mouse modelProteasome inhibitor bortezomibUnfolded protein responseEndometrial cancerPremenopausal womenFulvestrant resistanceStandard treatmentTamoxifen resistanceFulvestrant treatmentTumor regressionAgonist effectsClinical trialsBreast cancerMouse modelFulvestrantTherapeutic benefitConverts androgensAdipose tissueInhibitor bortezomibBortezomib
2004
Targeted Therapies for Cancer 2004
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapies for Cancer 2004. American Journal Of Clinical Pathology 2004, 122: 598-609. PMID: 15487459, DOI: 10.1309/5cwpu41afr1vym3f.Peer-Reviewed Original ResearchConceptsBcr/abl-positive chronic myelogenous leukemiaNon-small cell lung cancerEmergence of trastuzumabMetastatic colorectal cancerMetastatic breast cancerCell lung cancerRoute of administrationChronic myelogenous leukemiaProteasome inhibitor bortezomibEpidermal growth factor receptor (EGFR) geneNew therapeutic agentsEpidermal growth factor receptorSpecific genetic defectsTargeted anticancer therapiesGrowth factor receptorAgent bevacizumabGrowth factor receptor geneMolecular diagnosticsColorectal cancerCancer patientsLung cancerHematologic malignanciesImatinib mesylateTargeted therapyBreast cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply